Institutional members access full text with Ovid®

Share this article on:

Spontaneous Reports of Seizure in Association With Leuprolide (Lupron Depot), Goserelin (Zoladex Implant), and Naferelin (Synarel Nasal Spray)

Gatti, Jasmine MD; Brinker, Allen MD; Avigan, Mark MD

doi: 10.1097/AOG.0b013e31828c9cb3
Departments: Letters to the Editor

U.S. Food and Drug Administration Office of Surveillance and Epidemiology Silver Spring, Maryland

Letters to the Editor Guidelines. Letters posing a question or challenge to an article appearing in Obstetrics & Gynecology should be submitted within 6 weeks of the article’s publication online. Letters received after 6 weeks will rarely be considered. Letters should not exceed 350 words, including signatures and 5 references. A word count should be provided. The maximum number of authors permitted is four, and a corresponding author should be designated (and contact information listed). Letters will be published at the discretion of the Editor. The Editor may send the letter to the authors of the original paper so their comments may be published simultaneously. The Editor reserves the right to edit and shorten letters. A signed author agreement form is required from all authors before publication. Letters should be submitted using the Obstetrics & Gynecology online submission and review system, Editorial Manager (http://ong.edmgr.com).

Financial Disclosure: The authors did not report any potential conflicts of interest.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as reflecting the views of the U.S. Food and Drug Administration.

© 2013 by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.